HIV-1, Vpr and the cell cycle

Current Biology

Volumn 6, Issue 9, 1996, Pages 1096-1103

  Emerman, Michael ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0030250588     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(02)00676-0     Document Type: Article

References (84)

1. Nottet HS, Gendelman HE: Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol Today 1995, 16:441-448.
2. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181.
3. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P: Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993, 67:3345-3356.
4. Sotoramirez LE, Renjifo B, McLane MF, Marlink R, Ohara C, Sutthent R, Wasi C, Vithayasai P, Vithayasai V, Apichartpiyakul C, et al.: HIV-1 Langerhans cell tropism associated with heterosexual transmission of HIV. Science 1996, 271:1291-1293.
5. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Ornestein JM, Kotler DP, Fauci AS: HIV-1 infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
6. Embretson J, Zupancic M, Ribase JL, Burke A, Racz P, Tenner-Racz K, Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV-1 during the incubation period of AIDS. Nature 1993, 362:359-362.
7. + lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
8. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1585.
9. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bohoeffer S, Nowak MA, Hahn BH, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
10. Sprent J, Tough D: HIV-1 results in the frame. CD4+ cell turnover. Nature 1995, 375:194;198.
11. Gallo R, Wong-Staal F, Montagnier L, Haseltine WA, Yoshida M: HIV/HTLV gene nomenclature. Nature 1988, 333:504.
12. Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M: Nucleotide sequence of the AIDS virus, LAV. Cell 1985, 40:9-17.
13. Human retroviruses and AIDS. Edited by Myers G, Wain-Hobson S, Henderson LE, Korber B, Jeang K-T, Pavlakis GN. Los Alamos: Los Alamos National Laboratory; 1994.
14. Mustafa F, Robinson HL: Context-dependent role of human immunodeficiency virus type 1 auxiliary genes in the establishment of chronic virus producers. J Virol 1993, 67:6909-6915.
15. Rogel M, Wu L, Emerman M: The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995, 69:882-888.
16. Planelles V, Bachelerie F, Jowett JBM, Haislip A, Xie Y, P. B, Masuda T, Chen ISY: Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol 1995, 69:5883-5889.
17. Nakaya T, Fujinaga K, Kishi M, Oka S, Kurata T, Jones IM, Ikuta K: Nonsense mutations in the vpr gene of HIV-1 during in vitro virus passage and in HIV-1 carrier-derived peripheral blood mononuclear cells. FEBS Lett 1994, 354:17-22.
18. cdc2-cyclin B. J Virol 1995, 69:6859-6864.
19. Jowett JBM, Plannelles V, Poon B, Shah NP, Chen M-L, Chen ISY: The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 1995, 69:6304-6313.
20. cdc2 activity. J Virol 1995, 69:6705-6711.
21. Bartz S, Rogel ME, Emerman M: Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 1996, 70:2324-2331.
22. Levy DN, Fernandes LS, Williams WV, Weiner DB: Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 1993, 72:541-550.
23. Cohen EA, Terwilliger EF, Jalinoos Y, Proulx J, Sodroski JG, Haseltine WA: Identification of HIV-1 vpr product and function. J Acquired Immune Deficiency Syndromes 1990, 3:11-18.
24. Levy DN, Refaeli Y, Weiner DB: Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 1995, 69:1243-1252.
25. Coleman TR, Dunphy WG: Cdc2 regulatory factors. Curr Opin Cell Biol 1994, 6:877-882.
26. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ: Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995, 270:25564-25569.
27. Refaeli Y, Levy DN, Weiner DB: The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci USA 1995, 92:3621-3625.
28. Bouhamdan M, Benichou S, Rey F, Navarro JM, Agostini I, Spire B, Camonis J, Slupphaug G, Vigne R, Benarous R, Sire J: Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol 1996, 70:697-704.
29. Burgers PM, Klein MB: Selection by genetic transformation of a Saccharomyces cerevisiae mutant defective for the nuclear uracil-DNA-glycosylase. J Bacteriol 1986, 166:905-913.
30. Percival KJ, Klein MB, Burgers PM: Molecular cloning and primary structure of the uracil-DNA-glycosylase gene from Saccharomyces cerevisiae. J Biol Chem 1989, 264:2593-2598.
31. Mayer-Jaekel R, Hemmings B: Protein phosphatase 2A - a 'menage à trois'. Trends Cell Biol 1994, 4:287-291.
32. Sato A, Yoshimoto J, Isaka Y, Miki S, Suyama A, Adachi A, Hayami M, Fujiwara T, Yoshie O: Evidence for direct association of Vpr and matrix protein p17 within the HIV-1 virion. Virology 1996, 220:208-212.
33. Li MS, Garciaasua G, Bhattacharyya U, Mascagni P, Austen BM, Roberts MM: The Vpr protein of human immunodeficiency virus type 1 binds to nucleocapsid protein p7 in vitro. Biochem Biophys Res Commun 1996, 218:352-355.
34. gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol 1996, 70:159-164.
35. MacReadie IG, Castelli LA, Hewish DR, Kirkpatrick A, Ward AC, Azad AA: A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. Proc Natl Acad Sci USA 1995, 92:2770-2774.
36. Zhao Y, Cao J, O'Gorman M, Yogev R: Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J Virol 1996, in press.
37. Zack JA, Haislip AM, Krogstad P, Chen IS: Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992, 66:1717-1725.
38. Stevenson M, Stanwick T, Dempsey M, Lamonica C: HIV-1 replication is controlled at the level of T-cell activation and proviral integration. EMBO J 1990, 9:1551-1560.
39. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen ISY: HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990, 61:213-222.
40. Weinberg JB, Mattews TJ, Cullen BR, Malim MH: Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 1991, 174:1477-1482.
41. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M: Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 1992, 89:6580-6584.
42. Lewis P, Hensel M, Emerman M: Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992, 11:3053-3058.
43. Boettiger D, Temin H: Light inactivation of focus formation by chicken embryo fibroblasts infected with avian sarcoma virus in the presence of 5-bromodeoxyuridine. Nature 1970, 228:622-624.
44. Varmus H, Padgett T, Heasley S, Simon G, Bishop J: Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA. Cell 1977, 11:307-319.
45. Roe T, Reynolds TC, Yu G, Brown PO: Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993, 12:2099-2108.
46. Lewis PF, Emerman M: Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994, 68:510-516.
47. Schuitemaker H, Kootstra N, Fouchier R, Hooibrink B, Miedema F: Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J 1994, 13:5929-5936.
48. Heinzinger N, Baca Regen L, Stevenson M, Gendelman HE: Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1. Virology 1995, 206:731-735.
49. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
50. Goldfarb DS: Simply MArvelous nuclear transport. Curr Biol 1995, 5:570-573.
51. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubei A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M: A nuclear targeting signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993, 365:666-669.
52. von Schwedler U, Kornbluth RS, Trono D: The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994, 91:6992-6996.
53. Heinzinger N, Bukrinsky M, Haggerty S, Ragland A, Kewal Ramani V, Lee M, Gendelman H, Ratner L, Stevenson M, Emerman M: The HIV-1 Vpr protein influences nuclear targeting of viral nucleic acids in non-dividing cells. Proc Natl Acad Sci USA 1994, 91:7311-7315.
54. Gallay P, Swingler S, Aiken C, Trono D: HIV-1 infection of non-dividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995, 80:379-388.
55. Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgall TE, Lewis RE, Stevenson M: Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci USA 1996, 93:367-371.
56. Gallay P, Stitt V, Mundy C, Oettinger M, Trono D: Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 1996, 70:1027-1032.
57. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman HE, Ratner L: Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol 1992, 66:3925-3931.
58. Connor RI, Chen KB, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology 1995, 206:935-944.
59. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R: Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 1994, 200:623-631.
60. Freed EO, Englund G, Martin MA: Role of the basic domain of human immunodeficiency virus type 1 matrix protein in macrophage infection. J Virol 1995, 69:3949-3954.
61. Paxton W, Connor RI, Landau NR: Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993, 67:7229-7237.
62. Lavall'ee C, Yao XJ, Ladha A, Gottlinger H, Haseltine WA, Cohen EA: Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J Virol 1994, 68:1926-1934.
63. gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995, 69:6873-6879.
64. gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol 1995, 69:2759-2764.
65. Lu YL, Spearman P, Ratner L: Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 1993, 67:6542-6550.
66. Mahalingam S, Collman RG, Patel M, Monken CE, Srinivasan A: Functional analysis of HIV-1 Vpr: identification of determinants essential for subcellular localization. Virology 1995, 212:331-339.
67. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR: Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 1995, 69:7909-7916.
68. Zhao LJ, Wang L, Mukherjee S, Narayan O: Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J Biol Chem 1994, 269:32131-32137.
69. Michaud N, Goldfarb DS: Multiple pathways in nuclear transport: the import of U2 snRNP occurs by a novel kinetic pathway. J Cell Biol 1991, 112:215-223.
70. Moran E: Interaction of adenoviral proteins with pRB and p53. FASEB J 1993, 7:880-885.
71. Ludlow JW: Interactions between SV40 large-tumor antigen and the growth-suppressor proteins pRB and p53. FASEB J 1993, 7:866-871.
72. Jung JU, Stager M, Desrosiers RC: Virus-encoded cyclin. Mol Cell Biol 1994, 14:7235-7244.
73. Aldrovandi GM, Zack JA: Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in Scid-Hu mice. J Virol 1996, 70:1505-1511.
74. Wolinsky SM, Korber BTN, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao YZ, Ho DD, Safrit JT, Koup RA: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996, 272:537-542.
75. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
76. Planelles V, Jowett JB, Li Q, Xie Y, Hahn B, Chen ISY: Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol 1996, 70:2516-2524.
77. KewalRamani VN, Park CS, Gallomabardo PA, Emerman M: Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect. Virology 1996, 218:326-334.
78. Gibbs JS, Regier DA, Desrosiers RC: Construction and in vitro properties of SIVmac mutants with deletions in 'nonessential' genes. AIDS Res Hum Retrovir 1994, 10:607-616.
79. SM. EMBO J 1996, in press.
80. Greenberg AH, Litchfield DW: Granzymes and apoptosis: targeting the cell cycle. Curr Top Microbiol Immunol 1995, 198:95-119.
81. Chen G, Shi L, Litchfield DW, Greenberg AH: Rescue from granzyme B-induced apoptosis by Wee1 kinase. J Exp Med 1995, 181:2295-2300.
82. Moss PA, Rowland-Jones SL, Frodsham PM, McAdam S, Giangrande P, McMichael AJ, Bell JI: Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 1995, 92:5773-5777.
83. Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, Daniel MD, Desrosiers RC: Progression to AIDS in the absence of a gene for vpr or vpx. J Virol 1995, 69:2378-2383.
84. Hoch J, Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Dittmer U, Hunsmann G, Fuchs D, Muller J, Sopper S, et al.: vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol 1995, 69:4807-4813.